Drugs / Bacterial Lysate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05064631 | Jan 2022 → Jun 2024 | asthma, respiratory tract infectious disorder | Queen Mary University of London | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacterial Lysate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05064631 ↗ |
| Route | Oral | “Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 12-24 months” NCT05064631 ↗ |